Views & Analysis What is ‘affordable’? The reality of the PPRS PPRS impact: has it kept the branded medicines bill within affordable limits?
Views & Analysis Unstable and unpredictable? The reality of the PPRS Has the UK PPRS scheme met its five objectives?
Views & Analysis The rise and fall of PPRS payments How contributions from the updated PPRS have affected the DH budget for the NHS.
News UK government hires ex-pharma chief to lead pricing talks wi... The Department of Health has appointed a former UK head of Sanofi and Teva to be its chief commerci
News NHS should pay for medicines based on outcomes, argues Novar... A new report from the Social Market Foundation think tank argues that the UK’s National Health Service should switch to paying for medicines based on patient outcomes.
Views & Analysis Hung parliament: who will pharma negotiate with on new PPRS? Who could influence the makeup of the new PPRS?
News Pushback against Kennedy's mRNA decision builds The decision by HHS to cut funding for mRNA vaccines has caused dismay among scientists and public health experts, who have labelled it wrong-headed.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
